Table 1.
Demographics
| Characteristic | N (%) |
|---|---|
| Median age, years (range) | 56 (25–89) |
| Male | 44 (55) |
| Stage | |
| IIIc | 9 (11) |
| IV M1a/b | 17 (21) |
| IV M1c | 54 (68) |
| ≥1 prior therapy | 9 (11) |
| Anti-CTLA-4/PD-1 regimen | |
| Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg | 76 (95) |
| Pembrolizumab 2 mg/kg + Ipilimumab 1 mg/kg | 4 (5) |
| Number of aCTLA4 + aPD1 doses | |
| 1 | 21 (26) |
| 2 | 26 (33) |
| 3 | 21 (26) |
| 4 | 12 (15) |
| Length of steroid taper, days (median, range) | 35 (5–240) |
| Duration between last aCTLA4 + aPD1 dose and aPD1 resumption, days (median, range) | 58 (14–395) |
CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death 1.